Imunon Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

ImunonDer Gewinn des Unternehmens wird voraussichtlich um 19.6% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 82.9% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 36% pro Jahr wachsen.

Wichtige Informationen

-19.6%

Wachstumsrate der Gewinne

36.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	27.1%
Wachstumsrate der Einnahmen	82.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	31 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Celsion changes name to Imunon (IMNN)

Sep 19

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

Sep 01

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:IMNN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-35	-45	-46	4
12/31/2025	N/A	-27	-37	-34	4
12/31/2024	N/A	-22	-29	-29	4
6/30/2024	N/A	-18	-19	-19	N/A
3/31/2024	N/A	-19	-21	-21	N/A
12/31/2023	N/A	-20	-19	-19	N/A
9/30/2023	0	-28	-21	-20	N/A
6/30/2023	0	-31	-21	-20	N/A
3/31/2023	0	-31	-19	-19	N/A
12/31/2022	1	-36	-23	-23	N/A
9/30/2022	1	-27	-23	-23	N/A
6/30/2022	1	-26	-23	-22	N/A
3/31/2022	1	-26	-20	-19	N/A
12/31/2021	1	-21	-17	-16	N/A
9/30/2021	1	-20	-15	-15	N/A
6/30/2021	1	-22	-15	-15	N/A
3/31/2021	1	-22	-16	-15	N/A
12/31/2020	1	-21	-16	-16	N/A
9/30/2020	1	-22	-18	-18	N/A
6/30/2020	1	-19	-18	-18	N/A
3/31/2020	1	-20	-20	-20	N/A
12/31/2019	1	-17	-21	-20	N/A
9/30/2019	1	-8	-9	-9	N/A
6/30/2019	1	-7	-9	-8	N/A
3/31/2019	1	-10	-8	-8	N/A
12/31/2018	1	-12	-7	-7	N/A
9/30/2018	1	-22	-17	-17	N/A
6/30/2018	1	-23	-18	-18	N/A
3/31/2018	1	-20	N/A	-18	N/A
12/31/2017	1	-21	N/A	-17	N/A
9/30/2017	1	-21	N/A	-17	N/A
6/30/2017	1	-22	N/A	-17	N/A
3/31/2017	1	-21	N/A	-17	N/A
12/31/2016	1	-22	N/A	-18	N/A
9/30/2016	1	-22	N/A	-18	N/A
6/30/2016	1	-20	N/A	-18	N/A
3/31/2016	1	-21	N/A	-20	N/A
12/31/2015	1	-22	N/A	-21	N/A
9/30/2015	1	-23	N/A	-23	N/A
6/30/2015	1	-26	N/A	-24	N/A
3/31/2015	1	-27	N/A	-22	N/A
12/31/2014	1	-25	N/A	-21	N/A
9/30/2014	1	-23	N/A	-18	N/A
6/30/2014	1	-20	N/A	-15	N/A
3/31/2014	1	-13	N/A	-16	N/A
12/31/2013	1	-13	N/A	-10	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IMNN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: IMNN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: IMNN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: IMNN wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: IMNN wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von IMNN in 3 Jahren voraussichtlich hoch sein wird

Imunon Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 11% to US$9.75

Price target decreased by 17% to US$10.00

Consensus EPS estimates upgraded to US$2.95 loss

Price target decreased by 19% to US$18.75

Price target decreased to US$24.00

Price target decreased to US$32.67

Recent updates

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Price target decreased by 11% to US$9.75

Imunon, Inc. announced that it has received $10 million in funding

New major risk - Shareholder dilution

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial

Price target decreased by 17% to US$10.00

IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc. to Report Q1, 2024 Results on May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New minor risk - Share price stability

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer

IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

New major risk - Financial position

IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors

New minor risk - Share price stability

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Consensus EPS estimates upgraded to US$2.95 loss

Price target decreased by 19% to US$18.75

Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Price target decreased to US$24.00

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion changes name to Imunon (IMNN)

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

First half 2022 earnings: EPS and revenues exceed analyst expectations

Celsion Q2 2022 Earnings Preview

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion adds Moderna chief commercial officer as CEO

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Celsion Corporation, Annual General Meeting, Jun 13, 2022

Price target decreased to US$32.67

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial At 2022 Aacr Annual Meeting

Celsion Corporation has completed a Follow-on Equity Offering in the amount of $7.000004 million.

Price target decreased to US$41.00

Full year 2021 earnings: EPS misses analyst expectations

Celsion Corporation Reports Impairment for the Fourth Quarter Ended December 31, 2021

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

Celsion Corporation announced that it expects to receive $28.5 million in funding

Is Celsion (NASDAQ:CLSN) Using Debt Sensibly?

Third quarter 2021 earnings released: US$0.063 loss per share (vs US$0.24 loss in 3Q 2020)

Celsion Corporation Reports T-cell and B-cell Response from In Vivo Studies with its PLACCINE DNA Vaccine Platform

First half 2021 earnings released: US$0.15 loss per share (vs US$0.37 loss in 1H 2020)

Is Celsion (NASDAQ:CLSN) Using Too Much Debt?